Randomized multicenter single-blind controlled trial on ozonated blood in COVID-19 severe pneumonia

Políclinica Nuestra Señora del Rosario0 个研究点目标入组 30 人开始时间: 2021年2月1日最近更新: 2021年5月10日

适应症

试验速览

暂无简介。

•1. Men and women over 18 years of age.
•2. Diagnosis of COVID-19 confirmed by positive nasopharyngeal PCR.
•3. Lung infiltrate confirmed by imaging test (chest X-ray or CT) + patient with severe pneumonia (failure of > = 1 organ or SpO2 ambient air of <90% or respiratory rate> = 30) with need for oxygen with nasal canula , Venturi mask, non-rebreathing mask, high-flow nasal goggles or non-invasive mechanical ventilation (NIMV).
•4. Evolution time of <2 weeks from symptom onset to recruitment.
•5. Acceptance to participate in the study and signing of the consent form
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•1. Patients who have received treatment with systemic ozone six months before admission to the hospital.
•2. Patients who have previously experienced some type of adverse reaction to ozone therapy.
•3. Patients who are aware of having a glucose-6-phosphate-dehydrogenase deficiency
•4. Patients who are not able to clearly understand the objectives and methodology of the study.
•5. Pregnant or lactating patients.
•6. Patients who are intubated with invasive mechanical ventilation.
•7. Patients with decompensated concomitant pathology and / or associated infectious pathology not related to COVID-19.

发起方

Políclinica Nuestra Señora del Rosario